Year: 2019

Form 8.3 – hVIVO Plc

Written by Customer Service on December 10, 2019. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

BAMKO Wins Industry-Best Five PPAI Pyramid Awards for 2020

Written by Customer Service on December 10, 2019. Posted in Public Companies.

SEMINOLE, Fla., Dec. 10, 2019 (GLOBE NEWSWIRE) — BAMKO®, LLC, the Branding Division of Superior Group of Companies™ (NASDAQ: SGC), has been announced as the winner of an industry-best five PPAI Pyramid Awards for 2020. Since 1958, Promotional Products Association International (“PPAI”) has been honoring the best branding campaigns in the promotional products industry with its annual Pyramid Awards. BAMKO’s five Pyramid Awards for 2020 are more than any other promotional products distributor in the entire industry.BAMKO, which specializes in the development and execution of high-profile merchandise campaigns for Fortune 1000 companies, was the winner of two Pyramid Awards for Technology in the eCommerce Website category, two Pyramid Awards for Client Programs in the Consumer Programs category, and another for Client Programs in...

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

Written by Customer Service on December 10, 2019. Posted in Public Companies.

FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia ModelMaster Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target EffectsCompany Plans to Submit an IND Application for FT819 during 1H20SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida.FT819 is derived...

EIM: Information on former CEO’s claim

Written by Customer Service on December 10, 2019. Posted in Public Companies.

Reference is made to a press release from 19 May regarding the claim of the former CEO, Gylfi Sigfússon, that the investigation of the District Prosecutor should be ceased.Today the Reykjavik District Court ruled in a specific part of the case where he claimed that the District Prosecutor should submit certain documents to the court, certain persons should be presented as witnesses, and that the District Prosecutor would be denied to submit a review from the Icelandic Competition Authority into the case.The court rejected all claims in this specific part of the case.Gylfi will refer this ruling to the Court of Appeal.

EIM: Upplýsingar vegna kröfu fyrrverandi forstjóra

Written by Customer Service on December 10, 2019. Posted in Public Companies.

Vísað er til fréttar frá 19. maí sl. um kröfu Gylfa Sigfússonar, fyrrverandi forstjóra, að rannsókn Héraðssaksóknara á hendur honum verði hætt.Í dag úrskurðaði héraðsdómur í afmörkuðum þætti málsins þar sem hann gerði kröfu um að Héraðssaksóknari legði fram tiltekin gögn, að tiltekin vitni myndu gefa skýrslu fyrir dómi og að Héraðssaksóknara yrði synjað um að leggja fram umsögn Samkeppniseftirlitsins.Héraðsdómur hafnaði öllum kröfunum í þessum afmarkaða þætti málsins.Gylfi mun vísa þessari niðurstöðu til Landsréttar.

Siyata Mobile Receives $450,000 Purchase Order to Equip Bus Fleet with its Uniden® UV350

Written by Customer Service on December 10, 2019. Posted in Public Companies.

MONTREAL, Dec. 10, 2019 (GLOBE NEWSWIRE) — Siyata Mobile Inc. (the “Company” or “Siyata”) (TSX-V:SIM / OTCQX:SYATF) is pleased to announce that a $450,000 purchase order has been received for a bus operating company to equip their fleet of buses with the Uniden® UV350.Marc Seelenfreund, CEO of Siyata Mobile, commented, “The UV350 is a great communications device for the bus market on both the North American and international stage. We believe that this will be a very strong vertical for Siyata as it well suits this market looking to migrate from Land Mobile Radio (LMR) technology to next generation Push-to-Talk over Cellular. In the U.S. alone, there are over 500,000 yellow school buses that require a safe and reliable emergency communications system and we are very committed to deliver on this opportunity.”Since...

New IP Target Outlined at Kubi East, Ghana AGM Results

Written by Customer Service on December 10, 2019. Posted in Public Companies.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIESSHARES ISSUED: 64,055,757VANCOUVER, British Columbia, Dec. 10, 2019 (GLOBE NEWSWIRE) — Asante Gold Corporation (CSE:ASE/ FRANKFURT:1A9) (“Asante” or the “Company”) announces that a new high induced polarization (IP) target has been discovered 350 to 500 metres to the east of our Kubi Main gold deposit, Obuasi-Dunkwa area, Ghana.The IP and co-incident high resistivity anomaly is interpreted as sulfide mineralization along the sheared contact of highly magnetic Tarkwaiian meta conglomerates, and strikes azimuth 020 degrees, a structural setting similar to that noted at the Kubi Main gold deposit. At Kubi, the tenor of the gold mineralization is directly related to the sulfide content in a distinct garnet and quartz rich unit. IP surveys...

New Flights From Austin to Boston and San Jose Start This Spring

Written by Customer Service on December 10, 2019. Posted in Public Companies.

FORT WORTH, Texas, Dec. 10, 2019 (GLOBE NEWSWIRE) — American Airlines is giving customers a treat this holiday season with the announcement of two new routes from the vibrant and eclectic city of Austin, Texas (AUS), to the capital of Silicon Valley, San Jose, California (SJC), and to the historical city of Boston (BOS). These new routes will operate twice daily beginning in April.The airline is also introducing unique service in support of special events like golf tournaments in Augusta, Georgia (AGS), music festivals in Palm Springs, California (PSP), and the annual visit to one of the nation’s biggest shareholder meetings with increased service to Omaha, Nebraska (OMA). Austin flights will be available for purchase starting Dec. 16 and special events flights will be available for purchase starting Dec. 22.New Austin flights takeoff...

ToughBuilt Amazon Storefront Update: November Sales Exceeds Average Monthly Revenue for First Seven Months of Operation by 75%

Written by Customer Service on December 10, 2019. Posted in Public Companies.

ToughBuilt Amazon Storefront Sales Should Have an Annualized Revenue Run Rate of Approximately $5.4 million Based Upon November SalesLAKE FOREST, CA, Dec. 10, 2019 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (”ToughBuilt”) (NASDAQ: TBLT; TBLTW), a cutting edge product design, manufacturer and distributor of innovative products, tools and other accessories for the professional and do-it-yourself construction industries, today announced that its U.S. and Canadian Amazon storefronts had sales of $450,000 for the month of November 2019 (or sales in the initial eight months of operation in excess of $2.25 million, up from the $1.8 million announced for the initial seven months of operation). This equated to an annualized run-rate of $5.4 million (based on November sales), which is 54% higher than the $3.5 million run-rate...

Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

Written by Customer Service on December 10, 2019. Posted in Public Companies.

Targeting mid-year 2020 to commence clinical trials of Brilacidin for UP/UPS indicationRegulatory documents submitted to health authorities for planned Ulcerative Colitis studyBEVERLY, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that Alfasigma S.p.A (“Alfasigma”), the licensee of Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), is targeting mid-year 2020 to commence clinical trials of Brilacidin for the UP/UPS indication.The Company is encouraged by the pace in which Alfasigma is moving expeditiously forward with clinical development of Brilacidin for UP/UPS. This is important to the Company on multiple levels.Innovation Pharmaceuticals is eligible for up to $24...

Year: 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals